MX377822B - Composición nasal que tiene propiedades antivirales. - Google Patents

Composición nasal que tiene propiedades antivirales.

Info

Publication number
MX377822B
MX377822B MX2017001899A MX2017001899A MX377822B MX 377822 B MX377822 B MX 377822B MX 2017001899 A MX2017001899 A MX 2017001899A MX 2017001899 A MX2017001899 A MX 2017001899A MX 377822 B MX377822 B MX 377822B
Authority
MX
Mexico
Prior art keywords
glucoside
composition
alkyl poly
antiviral properties
nasal composition
Prior art date
Application number
MX2017001899A
Other languages
English (en)
Other versions
MX2017001899A (es
Inventor
Amina Saaid
Original Assignee
Church & Dwight Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX377822(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Church & Dwight Co Inc filed Critical Church & Dwight Co Inc
Publication of MX2017001899A publication Critical patent/MX2017001899A/es
Publication of MX377822B publication Critical patent/MX377822B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición nasal que comprende una base salina, un agente activo y un alquil poli glucósido. Dicha composición nasal está indicada como antiviral, para el tratamiento profiláctico o terapéutico de enfermedades virales de las vías respiratorias superiores, preferiblemente, mediante pulverización o formación de aerosol (spray) de dicha composición a un paciente que lo necesite.
MX2017001899A 2014-08-16 2015-08-06 Composición nasal que tiene propiedades antivirales. MX377822B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14181206.5A EP2985019B1 (en) 2014-08-16 2014-08-16 Nasal composition having anti-viral properties
PCT/US2015/043962 WO2016028504A1 (en) 2014-08-16 2015-08-06 Nasal composition having anti-viral properties

Publications (2)

Publication Number Publication Date
MX2017001899A MX2017001899A (es) 2017-11-08
MX377822B true MX377822B (es) 2025-03-11

Family

ID=51355469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001899A MX377822B (es) 2014-08-16 2015-08-06 Composición nasal que tiene propiedades antivirales.

Country Status (4)

Country Link
US (1) US20170274083A1 (es)
EP (1) EP2985019B1 (es)
MX (1) MX377822B (es)
WO (1) WO2016028504A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111265590B (zh) * 2020-01-21 2022-03-01 华熙生物科技股份有限公司 一种用于鼻腔喷雾透明质酸冻干制剂及其制备方法和应用
EP3871652B1 (de) 2020-02-25 2025-01-15 Dr. Schumacher GmbH Wasserbasiertes tränkungsmittel für feuchttücher
TR202019326A2 (tr) 2020-11-30 2021-04-21 Haci Murat Mertoglu Ph değeri̇ sayesi̇nde anti̇vi̇ral etki̇ gösteren burun solüsyonu

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
EP0138572B1 (en) 1983-10-11 1990-07-25 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
US5079236A (en) 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
JPH0232013A (ja) 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk 点鼻剤
CA2129238A1 (en) 1992-02-10 1993-08-19 F. Richard Christ Bimodal molecular weight hyaluronate formulations and methods for using same
IT1271001B (it) 1994-07-26 1997-05-26 Poli Ind Chimica Spa Procedimento di preparazione di acido ialuronico mediante fermentazione con streptococcus
EP0806940B1 (en) 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
IT1287967B1 (it) 1996-10-17 1998-09-10 Fidia Spa In Amministrazione S Preparazioni farmaceutiche per uso anestetico locale
FR2768630B1 (fr) * 1997-09-22 2000-08-04 Ulice Sa Utilisation d'alkyl monoglucosides en tant que vecteurs moleculaires
FR2780650B1 (fr) 1998-07-03 2000-09-08 Goemar Lab Sa Solutions salines, leur procede de preparation et medicaments a base de ces solutions
US6004560A (en) 1998-11-16 1999-12-21 Hsu; Wu-Ching Nasal spray (drop) for treating fever/cold, and its preparation
US20050232868A1 (en) * 1999-10-19 2005-10-20 The Procter & Gamble Company Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
JP2004513071A (ja) 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 肺の弾性繊維損傷に関連した呼吸器疾患の治療方法
SE0004750D0 (sv) 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
DE10161110A1 (de) 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
EP1369113B1 (en) 2002-06-06 2006-11-22 CHIESI FARMACEUTICI S.p.A. Solubilisation of drugs in HFA propellant by means of emulsions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7060691B2 (en) 2002-10-10 2006-06-13 Giuseppe Petrigni Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases
FR2847818B1 (fr) 2002-11-28 2008-04-04 Agro Ind Rech S Et Dev Ard Composition pharmaceutique a base d'acide hyaluronique
DE20318634U1 (de) 2003-11-13 2004-02-26 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden
EP1718315A4 (en) 2004-02-06 2008-08-13 Univ Monash HIGH DOSE USE OF SULFATED POLYSACCHARIDES IN SHORT INTERVALS FOR THE TREATMENT OF INFECTIONS
US20050224201A1 (en) * 2004-04-08 2005-10-13 Kimberly-Clark Worldwide, Inc. Treated crimped multi-ply product
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
GB0426068D0 (en) 2004-11-29 2004-12-29 Passion For Life Healthcare Lt Composition with bacteria blocking action
MX2007010306A (es) * 2005-02-23 2007-09-26 Uab Research Foundation Vacunacion mejorada con alquil-glicosido.
GB0602325D0 (en) * 2006-02-06 2006-03-15 Remedy Res Ltd Virucidal compositions and uses
DE102006053374A1 (de) 2006-02-09 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz
ITMI20060742A1 (it) 2006-04-13 2007-10-14 Patrizia Pattini Composizioni antibatteriche per il trattamento di infezioni delle alte e basse via aeree
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
FR2915389B1 (fr) 2007-04-26 2012-12-21 De La Mer Laboratoire Utilisation de solutions ioniques isoosmotiques a base d'eau de mer pour la fabrication de dispositifs medicaux pour la prevention des complications du rhume courant
CN101317847B (zh) 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
KR101449687B1 (ko) 2008-03-13 2014-10-14 주식회사 바이오랜드 저분자 및 고분자 히알루론산과 유근피로부터 분리된다당체 추출물을 함유하는 노화방지용 조성물
US20100215730A1 (en) 2009-02-20 2010-08-26 Intrepid Therapeutics, Inc. Compositions for Nasal Administration of Phenothiazines
DE102011010668A1 (de) 2011-02-08 2012-08-09 Ursapharm Arzneimittel Gmbh Wässrige pharmazeutische Zusammensetzung zur Prävention und/oder Therapie allergisch gereizter Nasenschleimhaut und dessen Verwendung
EP4085899A1 (en) 2011-06-14 2022-11-09 Neurelis, Inc. Administration of benzodiazepine
ES2667854T3 (es) 2011-07-07 2018-05-14 Holy Stone Healthcare Co., Ltd. Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación
FR2977494B1 (fr) 2011-07-08 2013-08-16 Ayawane Compositions cosmetiques ou pharmaceutiques contenant des acides hyaluroniques de masses moleculaires differentes
ES2665254T3 (es) 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
US20130039950A1 (en) 2011-08-09 2013-02-14 Church & Dwight Co., Inc. Neti-pot packet mixture
KR101326472B1 (ko) * 2011-11-28 2013-11-08 가톨릭대학교 산학협력단 광천수를 함유한 비강 세척용 조성물
DE202013000377U1 (de) 2012-12-11 2013-12-12 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die topische Anwendung
CA2932237C (en) 2013-12-03 2022-12-13 Gerolymatos International S.A. Ionic aqueous compositions comprising sulfated polysaccharides

Also Published As

Publication number Publication date
EP2985019A1 (en) 2016-02-17
WO2016028504A1 (en) 2016-02-25
EP2985019B1 (en) 2021-10-20
US20170274083A1 (en) 2017-09-28
MX2017001899A (es) 2017-11-08

Similar Documents

Publication Publication Date Title
MX379907B (es) Composicion anticaspa en aerosol.
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
MX2015015421A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
MX2015015417A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
MX386298B (es) Composicion farmaceutica que comprende adalimumab.
MX2019007571A (es) Polimorfos.
EP3689998A4 (en) Propellant, propellant composition and atomizer
MX377302B (es) Composiciones para el cuidado personal con dos fases benéficas.
TR201902741T4 (tr) Kişisel Temizlik Bileşimleri
TWD175924S (zh) 香水瓶
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
PE20191159A1 (es) Pulverizador
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
MX2017001629A (es) Anticuerpo anti-orai1.
MX377822B (es) Composición nasal que tiene propiedades antivirales.
MX376853B (es) Odorante osmanthus.
PH12019500121A1 (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
MX374621B (es) Composición perfumante.